Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
News and Events
Real Endpoints, which provides development and implementation of proprietary tools, has named Jeff Berkowitz as CEO and member of the board of directors. Most recently, Mr. Berkowitz served as an executive VP at UnitedHealth Group, CEO of it Optum International business, and as a strategic leader of OptumRx, its PBM, Mr. Berkowitz is a PharmaVOICE Red Jacket - 2014.
October 16, 2018
PharmaVoiceRead full publication >
Attendee: Real Endpoints team
The Academy of Managed Care Pharmacy (AMCP) is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.
October 22, 2018
October 25, 2018
Orlando, FLevent >
by Richard Mark Kirkner
The first gene therapy to treat an inherited disease is out of the gate, but with a very high price tag. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation?
July 25, 2018
Managed Careread full article >
Panelist: Jane F. Barlow, MD, MPH, MBA
Real Endpoints LLC
To explore new models of payment and benefit designs for high-investment medications, the AMCP convened a stakeholder conference in Baltimore Maryland on July 24 and 25, 2018. Health care leaders representing health plans, integrated delivery systems, pharmacy benefit managers, employers, national professional associations, the federal government, and biopharmaceutical companies participated in the forum.
July 24, 2018
July 25, 2018
Baltimore, MDevent >
Recent Insightsview archive >
October 17, 2018
Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals. The news is a big blow for Ajovy (fremanezumab-vfrm), as Express Scripts covers 30% of commercially insured patients in the USread full insight article >
July 2, 2018
Confirmation bias: when innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. Industry and its investors need a clear, objective lens through which they can burn away confirmation bias and see the likely access barriers their drugs will face once approvedRead full insight article >
National Business Director
Top 5 Pharma
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
President , GlaxoSmithKline U.S.